Evidence map›Paper›PMID 39001563›Full record

ArticleInternational journal of cancer2024

Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.

Jacqueline A Turner, Robert J Van Gulick, William A Robinson, Tariq Mughal, Richard P Tobin, Morgan L MacBeth, Blair Holman, Anthony Classon, Stacey M Bagby, Betelehem W Yacob and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. MYC as a key target for melanoma therapy.Frontiers in cell and developmental biology · 2026
    Review
  5. Ancestry and somatic profile predict acral melanoma origin and prognosis.medRxiv : the preprint server for health sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Jacqueline A TurnerDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Robert J Van GulickDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
William A RobinsonDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Tariq MughalDivision of Hematology-Oncology, Tufts University Cancer Center, Boston, Massachusetts, USA.
Richard P TobinCenter for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Morgan L MacBethDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Blair HolmanDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Anthony ClassonFoundation Medicine Inc., Cambridge, Massachusetts, USA.
Stacey M BagbyDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Betelehem W YacobDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Sarah J HartmanDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Ian SilvermanIgnyta, Inc., San Diego, California, USA.
Victoria M VorwaldCenter for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Nicholas GordenDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rita GonzalezDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Laurie M GayFoundation Medicine Inc., Cambridge, Massachusetts, USA.
Siraj M AliFoundation Medicine Inc., Cambridge, Massachusetts, USA.
Adam BensonFoundation Medicine Inc., Cambridge, Massachusetts, USA.
Vincent A MillerFoundation Medicine Inc., Cambridge, Massachusetts, USA.
Jeffrey S RossFoundation Medicine Inc., Cambridge, Massachusetts, USA.
Todd M PittsDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Matthew J RiothDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Karl D LewisDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Theresa MedinaDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Martin D McCarterCenter for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rene GonzalezDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Kasey L CoutsDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-2088-2229

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
American Cancer Society IRG-16-184-56Moore Family FoundationNCI NIH HHS NIH/NCI CCSG P30CA046934NCI NIH HHS P30 CA046934Patten-Davis FoundationPaul R. Ohara II Seed Grant Program
6 · The paper itself

Abstract

Despite advancements in treating cutaneous melanoma, patients with acral and mucosal (A/M) melanomas still have limited therapeutic options and poor prognoses. We analyzed 156 melanomas (101 cutaneous, 28 acral, and 27 mucosal) using the Foundation One cancer-gene specific clinical testing platform and identified new, potentially targetable genomic alterations (GAs) in specific anatomic sites of A/M melanomas. Using novel pre-clinical models of A/M melanoma, we demonstrate that several GAs and corresponding oncogenic pathways associated with cutaneous melanomas are similarly targetable in A/M melanomas. Other alterations, including MYC and CRKL amplifications, were unique to A/M melanomas and susceptible to indirect targeting using the BRD4 inhibitor JQ1 or Src/ABL inhibitor dasatinib, respectively. We further identified new, actionable A/M-specific alterations, including an inactivating NF2 fusion in a mucosal melanoma responsive to dasatinib in vivo. Our study highlights new molecular differences between cutaneous and A/M melanomas, and across different anatomic sites within A/M, which may change clinical testing and treatment paradigms for these rare melanomas.

Indexed as

DasatinibMelanomaMucous MembraneSkin NeoplasmsAdultAgedAnimalsAzepinesCell Line, TumorFemaleGene Expression ProfilingGenomicsHumansMaleMiceMiddle AgedAzepinesDasatinib(+)-JQ1 compoundTriazolesacralCRKLdasatinibfusionsmelanomamucosalMYCNF2

Identifiers

PMID39001563
PMCPMC11570350

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.